- Home
- GH vs SNEX Comparison
GH vs SNEX Comparison
Compare GH & SNEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- SNEX
- Stock Information
- Founded
- GH 2011
- SNEX 1924
- Country
- GH United States
- SNEX United States
- Employees
- GH N/A
- SNEX N/A
- Industry
- GH Medical Specialities
- SNEX Investment Bankers/Brokers/Service
- Sector
- GH Health Care
- SNEX Finance
- Exchange
- GH Nasdaq
- SNEX Nasdaq
- Market Cap
- GH 4.9B
- SNEX 5.3B
- IPO Year
- GH 2018
- SNEX 1994
- Fundamental
- Price
- GH $65.46
- SNEX $100.40
- Analyst Decision
- GH Strong Buy
- SNEX Buy
- Analyst Count
- GH 22
- SNEX 1
- Target Price
- GH $64.91
- SNEX N/A
- AVG Volume (30 Days)
- GH 2.2M
- SNEX 402.3K
- Earning Date
- GH 10-29-2025
- SNEX 11-18-2025
- Dividend Yield
- GH N/A
- SNEX N/A
- EPS Growth
- GH N/A
- SNEX 21.85
- EPS
- GH N/A
- SNEX 5.86
- Revenue
- GH $828,849,000.00
- SNEX $129,411,800,000.00
- Revenue This Year
- GH $28.30
- SNEX N/A
- Revenue Next Year
- GH $22.98
- SNEX $22.66
- P/E Ratio
- GH N/A
- SNEX $17.11
- Revenue Growth
- GH 28.74
- SNEX 53.56
- 52 Week Low
- GH $20.14
- SNEX $55.85
- 52 Week High
- GH $68.23
- SNEX $106.98
- Technical
- Relative Strength Index (RSI)
- GH 59.00
- SNEX 53.45
- Support Level
- GH $61.00
- SNEX $95.36
- Resistance Level
- GH $68.22
- SNEX $104.11
- Average True Range (ATR)
- GH 2.50
- SNEX 3.11
- MACD
- GH 0.12
- SNEX 0.06
- Stochastic Oscillator
- GH 64.47
- SNEX 50.53
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About SNEX StoneX Group Inc.
StoneX Group Inc is a Global brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, Global payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: Commercial, Institutional, Self-Directed/Retail, and Payments. Its customers include governmental and nongovernmental organizations, commercial banks, brokers, institutional investors, and investment banks. The company operates in the United States, South America, Europe, the Middle East and Asia, and other countries, out of which the majority of revenue is generated from the Middle East and Asia Region.